Business Overview
Ranbaxy Pharmaceuticals Inc. (RPI), a wholly owned subsidiary
of Ranbaxy Laboratories Limited. (RLL), was established in the
U.S. in 1994. RPI began marketing FDA approved generic products
in the U.S. in 1998 after receiving its first FDA approval for
Cefaclor, a broad spectrum anti-infective agent.
Ranbaxy Laboratories Inc. (RLI), also a wholly owned subsidiary
of Ranbaxy Laboratories Limited. (RLL), is the branded prescription
division in the U.S. RLI has been expanding and growing on the
strength of Ranbaxy’s R&D efforts, and continuing
exploration of novel drug delivery systems (NDDS), licensing
activities, mergers and acquisitions. RLI is expanding the visibility
and presence of the Ranbaxy name by bringing value-added brand
products to the market.
Ranbaxy Pharmaceuticals Inc. and RLI have
built on RLL's years of successful pharmaceutical experience
and expertise. Ranbaxy has positioned itself as a robust and
capable player in the U.S. market through the combined commitment
of RPI and RLI to developing new and innovative
products and a rapidly expanding generic
and brand product portfolio.
|
